# OnCo record smouldering-myeloma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/smouldering-myeloma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "smouldering-myeloma" ;
  schema:name "Smouldering multiple myeloma"@en ;
  schema:alternateName "Smoldering multiple myeloma"@en, "SMM"@en, "High-risk smouldering myeloma"@en, "Asymptomatic myeloma"@en ;
  schema:description "Smouldering myeloma is myeloma that has not yet damaged bones, kidneys or blood counts. Most people are watched, but those at high risk of progressing can now be treated: the AQUILA trial showed daratumumab alone delays active myeloma, and it was approved for this use in 2025."@en ;
  schema:url <https://onco.cc/cancers/smouldering-myeloma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Smouldering_myeloma> ;
  schema:citation <https://en.wikipedia.org/wiki/Smouldering_myeloma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/whole-body-mri/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/cd38/> ;
  onco:terms <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/terms/high-risk-myeloma/>, <https://onco.cc/terms/r-iss/> ;
  onco:pipeline <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/trials/istopmm/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct05955508/> ;
  onco:standardOfCare <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/technologies/whole-body-mri/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct05955508/>, <https://onco.cc/trials/nct04270409/>, <https://onco.cc/trials/istopmm/> .